-
-
-
-
-
-
-
Ligand Pharma (LGND) Offers $15M to Acquire Assets of Novan (NOVN)
-
-
-
-
-
-
-
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
-
-
-
-
-
-
-
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
-
-
-
-
-
-
-
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
-
-
-
-
-
-
-
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Novan (NOVN) Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology
-
1,155,049 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

